Colonoscopy Clinical Trial
Official title:
Percentage Visualized Mucosa as a Marker for the Quality of Colonoscopy
Primary hypothesis: The percentage of mucosa visualized during the withdrawal of a
colonoscopy with reference to the position in the colon by means of the scope-guide is an
appropriate parameter for assessment of the quality of colonoscopy and correlates with the
probability of the detection of adenomas.
Secondary hypothesis:
The investigators hypothesize that the percentage of visualized mucosa differs according
patient specific parameters (e.g. gender, age, BMI, bowel preparation), procedure specific
parameters (e.g. patient position, device, buscopan, fentanyl, withdrawal time) and
investigator specific parameters (professional experience as resident and consultant).
Study Procedure/Evaluation:
The endoscopic images and scope guide from colonoscopy of 500 patients will be filmed. The
investigators will correlate the detection of at least one adenoma in the cohort of included
patients with the percentage of visualized mucosa during the withdrawal of a colonoscopy.
Additional endpoints concerning the quality of the colonoscopy will be assessed as well.
PROJECT OBJECTIVES AND DESIGN 1.1 Hypothesis Primary hypothesis: The percentage of mucosa
visualized during the withdrawal of a colonoscopy with reference to the position in the colon
by means of the scope-guide is an appropriate parameter for assessment of the quality of
colonoscopy and correlates with the probability of the detection of adenomas.
Secondary hypothesis:
The investigators hypothesize that the percentage of visualized mucosa differs according
patient specific parameters (e.g. gender, age, BMI, bowel preparation), procedure specific
parameters (e.g. patient position, device, buscopan, fentanyl, withdrawal time) and
investigator specific parameters (professional experience as resident and consultant).
STUDY DESIGN AND PROCEDURES 2.1 Study Design: The investigators will perform a
non-interventional, single center exploratory study. Only total colonoscopies will be
included. All of the examinations will be performed by board-certified specialists or fellows
in training, supervised by the former. The investigators will enroll only participants who
will have an explicit indication, in other words who will get a colonoscopy anyway.
Therefore, colonoscopies will be conducted for a wide variety of indications including, but
not limited, to CRC screening, CRC/ adenoma surveillance, abdominal symptoms such as pain,
irregular defecation (diarrhea or constipation), gastrointestinal occult or overt bleeding,
family history of polyps or CRC, prior colonic resection, hereditary polyposis syndromes and
inflammatory bowel diseases (IBD). Since the study does not pose any additional risk to the
participants (the only thing which changes for the patient is that the endoscopic images from
colonoscopy and scope guide will be filmed), the enrollment can be done during consultation
hour, at the ward or shortly before a colonoscopy.
2.2 Recruitment, screening and informed consent procedure: Patients will be recruited by the
project team in the Department of Visceral Surgery and Medicine at the Inselspital. The
patient will be provided with information regarding the study. If the patient shows interest,
the investigator will explain the study protocol, answer questions and check inclusion and
exclusion criteria. For this study, no compensatory fee will be paid.
2.3 Study procedures: If the patient agrees to participate in the study and has signed the
informed consent the colonoscopy will be performed in the usual setting and using general
safety measures. The endoscopist will start filming all the phases of the colonoscopy and the
position of the scope-guide simultaneously. Both films will be uploaded to the local server
and then cut and analyzed with the help of iMovie. The only study procedure specific for the
study is the filming and no other study specific measures will be taken.
Basic parameters of patient history and colonoscopy procedure will be recorded (compare CRF).
As always, any findings of the colonoscopy will be reported to the participant/ patient after
the procedure.
2.4 Withdrawal and discontinuation: If an individual withdraws informed consent after the
colonoscopy or during the analysis of the data, he/she will be withdrawn from the project.
All videos will be anonymized. In case of withdrawal, patient data and videos will not be
considered for study purposes and will be deleted completely.
STATISTICS AND METHODOLOGY 3.1 Evaluation of Videos: All videos will be anonymized. Then the
percentage of visible mucosa and lumen during withdrawal will be determined in each video.
The scope-guide will allow to correlate the images with the position of the colonoscope
within the colon. The investigators will record the amount of time spend in colon segments
such as the cecum, ascending colon, right flexure, right transverse colon, left transverse
colon, left flexure, descending colon, sigma and rectum. For each of these segments, the
investigators will record the amount of time with good mucosa visibility and poor mucosa
visibility.
In addition to manual analysis, computer-aided analysis and artificial intelligence methods
will be developed to assist the evaluation of the videos. The development of computer-aided
methods consists of two phases. In the first phase, frames in the video will be extracted as
individual images. Experienced physicians will be assigned to annotate the images. The
position of the scope-guide will be extracted for the annotation. Then a classifier based on
deep neural network will be trained on these annotated images. The percentage of visible
mucosa and lumen during withdrawal will be determined in each video based on the
classification results of each individual frame. The classification according to the
scope-guide will allow to correlate the images with the position of the colonoscope within
the colon. The amount of time spending in colon segments such as the cecum, ascending colon,
right flexure, right transverse colon, left transverse colon, left flexure, descending colon,
sigma and rectum will be determined based on deep learning prediction results. Each frame
will be classified to good mucosa visibility and poor mucosa visibility and the amount of
time with good mucosa visibility and poor mucosa visibility of each of the segments will be
determined accordingly. In the second phase, videos will be analysed directly with deep
learning methods and the consistency between the frames will be explored during the analysis
to improve the accuracy.
The investigators will also analyse advancements of the endoscope from the anus to the cecum.
To this end, the time until each of the segments is reached will be recorded as well as all
loops which have formed within the colon.
3.2 Statistical analysis plan 3.2.1. Statistical evaluation of the primary endpoint For
evaluation of the primary endpoint (adenoma detection rate as a function of mucosa
visibility) the investigators will rank all investigations regarding mucosa visibility and
will divide the study population in 50% individuals with the best mucosa visibility and
compare this number to the 50% of individuals with the worst mucosa visibility. They will
compare the fraction of individuals with at least 1 detected adenoma to individuals without a
detected adenoma (Fisher exact test). They will subsequently use multivariate logistic
regression to correct for confounders (age, gender, family history of CRC, personal history
of adenomas, advanced adenomas, carcinomas, BMI and bowel preparation).
3.2.2. Power analysis Our study is exploratory and no proper power analysis is possible. To
provide an estimation the investigators assume that the effect of poor vs. good mucosa
visibility will be as good as the effect of one of a number of technical devices recently
tested in clinical studies to improve adenoma detection during colonoscopy. Such new
technical devices (NTDs) include mucosa caps attached to the tips of the endoscope which
flatten and stretch the mucosa or lenses to improve the field and angle of view. In a recent
meta-analysis, NTDs increased the odds of adenoma detection by 35% (odds ratio 1.35) 25. In a
screening colonoscopy, an adenoma detection rate of at least 20% would be expected 26 (i.e.
50 individuals with at least one adenoma among 250 individuals). In individuals with optimal
mucosa visibility, this number would be 35% higher (i.e. 68 in 250 individuals). According to
the power analysis using G* Power 3.1 27, 419 individuals would be needed to detect such a
difference (i.e. 20% vs. 27% adenoma detection) with a power of 80% at an alpha level of 5%.
The Investigators are aiming to include 500 individuals to account for an estimated 15% of
investigations which could not be evaluated due to incomplete examinations or technical
problems.
3.2.3 Statistical analysis of the secondary endpoints For the secondary outcomes, observed
effects and interactions will be statistically substantiated by parametric and non-parametric
tests and/ or multivariate analyses considering confounders as appropriate. A p-value <0.05
will be considered significant.
3.3 Handling of missing data: The nature of this exploratory study allows for some tolerance
regarding missing data. Patients with incomplete or missing data/videos due to technical
problems will be excluded from the study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04101097 -
Training and Validation of Models of Factors to Predict Inadequate Bowel Preparation Colonoscopy
|
||
Completed |
NCT03247595 -
Testing How Well Magnesium Citrate Capsules Work as Preparation for a Colonoscopy
|
N/A | |
Completed |
NCT04214301 -
An Open-Label Preference Evaluation of BLI800
|
Phase 4 | |
Withdrawn |
NCT05754255 -
Comparison of High-flow Oxygen With or Without Nasal Positive Airway Pressure (PAP) During Propofol Sedation for Colonoscopy in an Ambulatory Surgical Center
|
N/A | |
Recruiting |
NCT02484105 -
Comforting Conversation During Colonoscopy: A Trial on Patient Satisfaction
|
Phase 4 | |
Active, not recruiting |
NCT02264249 -
Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation
|
N/A | |
Terminated |
NCT01978509 -
The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies
|
N/A | |
Completed |
NCT01964417 -
The Comparative Study Between Bowel Preparation Method
|
Phase 3 | |
Recruiting |
NCT01685970 -
Comparison of Same-day 2 Sachets Picosulfate Versus High Volume PEG for Afternoon Colonoscopy
|
Phase 3 | |
Completed |
NCT01518790 -
Short Course, Single-dose PEG 3350 for Colonoscopy Prep in Children
|
N/A | |
Recruiting |
NCT00748293 -
Achievement of Better Examinee Compliance on Colon Cleansing Using Commercialized Low-Residue Diet
|
N/A | |
Completed |
NCT00779649 -
MoviPrep® Versus HalfLytely®, Low-VolUme PEG Solutions for Colon Cleansing: An InvesTigator-blindEd, Randomized, Trial
|
Phase 4 | |
Completed |
NCT00671177 -
Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique
|
N/A | |
Completed |
NCT00380497 -
Pico-Salax Versus Poly-Ethylene Glycol for Bowel Cleanout Before Colonoscopy in Children
|
Phase 4 | |
Recruiting |
NCT00160823 -
Impact of a Self-Administered Information Leaflet on Adequacy of Colonic Cleansing for in-Hospital Patients
|
Phase 3 | |
Completed |
NCT00314418 -
Patient Position and Impact on Colonoscopy Time
|
N/A | |
Completed |
NCT00390598 -
PEG Solution (Laxabon®) 4L Versus Senna Glycoside (Pursennid® Ex-Lax) 36mg and PEG Solution (Laxabon®) 2L for Large Bowel Cleansing Prior to Colonoscopy
|
Phase 2/Phase 3 | |
Completed |
NCT00427089 -
Comparison of 2L NRL994 With NaP Preparation in Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening
|
Phase 3 | |
Completed |
NCT00209573 -
A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Elective Colonoscopy
|
Phase 3 | |
Completed |
NCT05823350 -
The Effect of Abdominal Massage on Pain and Distention After Colonoscopy
|
N/A |